Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: June 11th, 2012 - June 11th, 2013

Target Audience
The activity was developed for physicians, nurses, and pharmacists involved in the treatment of patients with mantle cell lymphoma.

Educational Objectives

Upon completion of this activity, the participant will be able to:

  • Analyze results of recent clinical trials investigating the incorporation of newer agents into mantle cell lymphoma (MCL) treatment
  • Discuss the safety and efficacy of adding radioimmunotherapy to chemotherapy regimens for patients with MCL
  • Summarize common toxicities associated with treatments for MCL, and identify current approaches to reduce or ameliorate these effects

Agenda - 1.25 hours

  • Articles/Commentaries: 60 minutes
  • Evaluation/Post-Test: 15 minutes

Physician Credit Designation
The Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical Learning Institute, Inc. and the Center of Excellence Media, LLC. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.

Registered Pharmacy Designation
Medical Learning Institute, Inc. (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-12-014-H01-P.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship( s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosures

Stephanie A. Gregory, MD, is on the advisory board for Genentech/Roche, and Spectrum Pharmaceuticals, and on the data safety monitoring board for Genentech/Roche.

Mitchell R. Smith, MD, PhD, is on the advisory board for Teva, and on the speaker’s bureau for Allos, Genentech, Millennium: The Takeda Oncology Company, and Spectrum Pharmaceuticals.

Barbara Rogers CRNP, MN, AOCN, ANP-BC, is on the advisory board for Celgene and Teva, and on the speakers bureau for Allos, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals and Teva.

*Dwight Kloth, PharmD, FCCP, BCOP, is a member of the Director of Pharmacy Advisory Boards for Amgen, Celgene, Eisai, Hospira, and Prostrakan.

*Content will include non-FDA-approved uses.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Name of Planner
or Manager
Company Reported Financial
Dana Delibovi COEXM Nothing to disclose
William J. Wong, MD MLI Nothing to disclose
Ryan Sims, CRNA, MS MLI Nothing to disclose
Shelley Chun, PharmD MLI Nothing to disclose

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Related Items
ASH Highlights on Non-Hodgkin Lymphoma: A Payer's and Pharmacist's Perspective
Dwight D. Kloth, PharmD, FCCP, BCOP, Gary C. Yee, PharmD, FCCP, BCOP
Supplements published on April 15, 2010
Considerations in Multiple Myeloma: Do Complete Responses Correlate with Clinical Benefit?
Sagar Lonial, MD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Jill M. Kolesar, PharmD, FCCP, BCPS
Supplements published on June 10, 2009
Last modified: March 21, 2014